Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Current status of biomarker research in neurology.
Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis.
Expression of switch-associated protein 70 is associated with lymphocyte activation and reduced disability in multiple sclerosis.
Neural Stem Cell Transplantation and CNS Diseases.
Thrombomodulin dependent protein C activation is required for mitochondrial function and myelination in the CNS.
Discovery of a new structural class of competitive hDHODH inhibitors with in vitro and in vivo anti-inflammatory, immunosuppressive effects.
A consensus initiative for the assessment of patients newly diagnosed with multiple sclerosis in Spain: the eXamina Project.
Synaptic Pathology in the Cerebellar Dentate Nucleus in Chronic Multiple Sclerosis.
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Assessing Functional Decline in Neurological Diseases Clinical Trials: Duration of Follow-Up - The Case of Multiple Sclerosis.
Rasch analysis of SF-Qualiveen in multiple sclerosis.
Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later.
Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific.
Walking fatigability in multiple sclerosis: A comparison between the 2- and the 6-minute walk test and an evaluation of associated factors.
Mitochondrial dysfunction and neurodegeneration in multiple sclerosis.
Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis.
A Choroid Plexus Epithelial Cell-based Model of the Human Blood-Cerebrospinal Fluid Barrier to Study Bacterial Infection from the Basolateral Side.
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.
Green tea EGCG, T-cell function, and T-cell-mediated autoimmune encephalomyelitis.
Coping strategies have a strong impact on quality of life, depression, and embitterment in patients with Cushing's disease.
Utilization of PET imaging in differential diagnostics between a tumefactive multiple sclerosis lesion and low-grade glioma.
Formation and disruption of functional domains in myelinated CNS axons.
Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations.
Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors.
Pages
« first
‹ previous
…
731
732
733
734
735
736
737
738
739
…
next ›
last »